GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nektar Therapeutics (NAS:NKTR) » Definitions » Cyclically Adjusted Book per Share

NKTR (Nektar Therapeutics) Cyclically Adjusted Book per Share : $58.84 (As of Mar. 2025)


View and export this data going back to 1994. Start your Free Trial

What is Nektar Therapeutics Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Nektar Therapeutics's adjusted book value per share for the three months ended in Mar. 2025 was $1.107. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $58.84 for the trailing ten years ended in Mar. 2025.

During the past 12 months, Nektar Therapeutics's average Cyclically Adjusted Book Growth Rate was 2.30% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 7.20% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 11.90% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was 14.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Nektar Therapeutics was 49.10% per year. The lowest was -26.40% per year. And the median was 0.60% per year.

As of today (2025-07-06), Nektar Therapeutics's current stock price is $24.76. Nektar Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was $58.84. Nektar Therapeutics's Cyclically Adjusted PB Ratio of today is 0.42.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Nektar Therapeutics was 130.74. The lowest was 0.12. And the median was 7.73.


Nektar Therapeutics Cyclically Adjusted Book per Share Historical Data

The historical data trend for Nektar Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nektar Therapeutics Cyclically Adjusted Book per Share Chart

Nektar Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 41.22 47.29 52.24 56.21 58.33

Nektar Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 57.53 58.17 58.30 58.33 58.84

Competitive Comparison of Nektar Therapeutics's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Nektar Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nektar Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nektar Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Nektar Therapeutics's Cyclically Adjusted PB Ratio falls into.


;
;

Nektar Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Nektar Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book= Book Value per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=1.107/134.9266*134.9266
=1.107

Current CPI (Mar. 2025) = 134.9266.

Nektar Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201506 3.983 100.684 5.338
201509 4.397 100.392 5.910
201512 0.713 99.792 0.964
201603 -0.030 100.470 -0.040
201606 -4.310 101.688 -5.719
201609 -7.387 101.861 -9.785
201612 8.628 101.863 11.429
201703 4.338 102.862 5.690
201706 0.326 103.349 0.426
201709 8.043 104.136 10.421
201712 8.258 104.011 10.713
201803 5.384 105.290 6.899
201806 161.860 106.317 205.416
201809 155.164 106.507 196.567
201812 148.464 105.998 188.982
201903 140.638 107.251 176.930
201906 133.501 108.070 166.678
201909 127.034 108.329 158.224
201912 119.435 108.420 148.634
202003 109.329 108.902 135.456
202006 105.380 108.767 130.725
202009 97.908 109.815 120.297
202012 89.730 109.897 110.167
202103 81.832 111.754 98.800
202106 73.863 114.631 86.940
202109 65.145 115.734 75.948
202112 54.954 117.630 63.035
202203 48.952 121.301 54.451
202206 36.716 125.017 39.626
202209 32.899 125.227 35.447
202212 29.165 125.222 31.425
202303 19.092 127.348 20.228
202306 15.539 128.729 16.287
202309 12.531 129.860 13.020
202312 10.266 129.419 10.703
202403 10.350 131.776 10.597
202406 6.494 132.554 6.610
202409 3.975 133.029 4.032
202412 4.904 133.157 4.969
202503 1.107 134.927 1.107

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Nektar Therapeutics  (NAS:NKTR) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Nektar Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=24.76/58.84
=0.42

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Nektar Therapeutics was 130.74. The lowest was 0.12. And the median was 7.73.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Nektar Therapeutics Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Nektar Therapeutics's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Nektar Therapeutics Business Description

Industry
Traded in Other Exchanges
Address
455 Mission Bay Boulevard South, San Francisco, CA, USA, 94158
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.
Executives
Howard W Robin director, officer: President & CEO
Jonathan Zalevsky officer: Chief R&D Officer 455 MISSION BAY BOULEVARD SOUTH, C/O NEKTAR THERAPEUTICS, SAN FRANCISCO CA 94158
Mark Andrew Wilson officer: SVP & General Counsel 1613 RAY DRIVE, BURLINGAME CA 94010
Robert Chess director, officer: Executive Chairman
Myriam Curet director 1020 KIFER ROAD, SUNNYVALE CA 94086
Jeffrey Robert Ajer director C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949
Sandra A. Gardiner officer: Chief Financial Officer CUTERA, INC., 3240 BAYSHORE BOULEVARD, BRISBANE CA 94005
Jillian B. Thomsen officer: VP & Chief Accounting Officer C/O NEKTAR THERAPEUTICS, 201 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Karin Eastham director C/O BURNHAM INSTITUTE FOR MEDICAL RESEAR, 10901 N. TORREY PINES ROAD, LA JOLLA CA 92037
Gil M Labrucherie officer: SVP, COO & CFO 150 INDUSTRIAL ROAD, SAN CARLOS CA 94070
John Northcott officer: SVP & Chief Commercial Officer 455 MISSION BAY BOULEVARD SOUTH, C/O NEKTAR THERAPEUTICS, SAN FRANCISCO CA 94158
Diana Brainard director C/O ALLOVIR, INC., 139 MAIN STREET, SUITE 500, CAMBRIDGE MA 02142
R Scott Greer director 6207 E. INDIAN BEND RD, PARADISE VALLEY AZ 85253
Lutz Lingnau director 15 INDIAN HOLLOW ROAD, MENDHAM NJ 07945
Stephen K Doberstein officer: Chief Scientific Officer 129 ELSIE STREET, SAN FRANCISCO CA 94110